Myeloproliferative neoplasms (MPNs) are diseases of the blood cells and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.

Cecilia BrownMyeloproliferative Neoplasms | February 2, 2023
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Read More
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 29, 2022
Ruben Mesa, MD, discusses his career in MPN treatment and research and notable abstracts at the 2022 ASH Annual Meeting.
Leah SherwoodMeeting News | December 20, 2022
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Patients with MPN have a high risk of death from cardiovascular causes.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Cecilia BrownMyeloproliferative Neoplasms | December 20, 2022
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Chadi Nabhan, MD, MBA, FACPVideo Insights | December 20, 2022
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Leah SherwoodVideo Insights | December 20, 2022
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Leah SherwoodMeeting News | December 12, 2022
Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera.
Keightley AmenMyeloproliferative Neoplasms | December 12, 2022
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Keightley AmenMeeting News | December 10, 2022
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
Kerri FitzgeraldMyeloproliferative Neoplasms | December 10, 2022
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Keightley AmenMeeting News | December 10, 2022
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
Keightley AmenMyeloproliferative Neoplasms | December 9, 2022
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
Keightley AmenMyeloproliferative Neoplasms | December 9, 2022
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
Keightley AmenMyeloproliferative Neoplasms | December 8, 2022
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
The National Comprehensive Cancer Network publishes new MPN guidelines.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Researchers published new classifications for MPNs and acute leukemias.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A large real-world study assessed patients who were diagnosed with myeloproliferative neoplasms before age 25.
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodMyelodysplastic Syndromes | June 23, 2022
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
Kerri FitzgeraldMyeloproliferative Neoplasms | June 23, 2022
Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF).
Leah LawrenceMyeloproliferative Neoplasms | June 13, 2022
Long-term results from the RESPONSE-2 trial confirm efficacy of ruxolitinib for PV.
Leah LawrenceMyeloproliferative Neoplasms | April 21, 2022
The NCCN now includes the oral JAK inhibitor pacritinib as a first-line treatment for certain myelofibrosis patients.
Sabrina AhleMyeloproliferative Neoplasms | March 2, 2022
In patients with high-risk essential thrombocythemia and polycythemia vera, both hydroxyurea and pegylated interferon-α.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Brandon MayMyeloproliferative Neoplasms | January 21, 2022
REVEAL is the largest prospective and contemporary cohort of patients with PV in the United States.
Leah LawrenceMyeloproliferative Neoplasms | January 21, 2022
Researchers shared a new single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven.
Patrick DalyMyeloproliferative Neoplasms | January 8, 2022
Clonal hematopoiesis of indeterminate potential was associated with a reduced risk of Alzheimer's disease dementia.
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Rebecca AraujoHodgkin Lymphoma | January 20, 2021
A research team in Norway found that previous hematological malignancies were associated with a subsequent diagnosis.
Latest News

March 24, 2023